Open AccessThe impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
Author(s) -
Lili Wang,
Zhen He,
Sen Yang,
Hong Tang,
Yufeng Wu,
Shaomei Li,
Baohui Han,
Kai Li,
Li Zhang,
Jianhua Shi,
Zhehai Wang,
Ying Cheng,
Jianxing He,
Yuankai Shi,
Weiqiang Chen,
Yi Luo,
Lin Wu,
Xiuwen Wang,
Nan Kang,
Fang Jin,
Jian Dong,
Baolan Li,
Yan Sun,
Qiming Wang
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.09.21
Subject(s) - medicine , vinorelbine , lung cancer , oncology , gefitinib , bevacizumab , pemetrexed , hazard ratio , progression free survival , epidermal growth factor receptor , chemotherapy , cancer , cisplatin , confidence interval
Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303 trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell lung cancer (NSCLC) patients. Meanwhile, the impact of previous therapy strategies on the efficiency of anlotinib still remains unknown.